Cambridge, UK, 30th October 2024 / Domainex, a multi-award winning, leading provider of drug discovery services, is proud to announce its inclusion in the very first edition of the Financial Times ‘Europe’s Long-Term Growth Champions’ special report compiled in partnership with Statista.
This study aimed to identify and highlight European enterprises with long-term sustained organic growth. The 300 companies included in the list were selected from across all sectors and over 30 countries and have all demonstrated substantial revenue growth between 2013 and 2023. The list builds on the established FT 1000 concept, which identifies Europe’s Fastest Growing Companies but focuses on rapid organic growth within 3 years.
Domainex has undergone significant change since 2013, with its team quadrupling to support a growing portfolio of global clients from the pharmaceutical, biotechnology and academic sectors. As a result of this growth, the company has needed to relocate to larger premises three times and currently has two high-end facilities in the Cambridge area, UK. The company has also expanded internationally and has opened an office in Cambridge, MA, to service the thriving biotechnology industry in North America.
During the last decade, the company has invested in broadening its service offerings and made significant investments in new technologies, including equipment, in its biophysics department. The company is considered a world leader in the field since becoming the first contract research organisation (CRO) to invest in MicroScale Thermophoresis (MST) technology in 2016 and has introduced cryo-EM as a new service. The company also rapidly established and grew its bioanalytical department during the report period. Recently, the company has adopted new methods and technologies in chemistry, such as High Throughput Experimentation approaches, Direct-to-Biology (D2B) and flow chemistry.
Inclusion in this prestigious list follows Domainex’s recent achievement of the King’s Award for Enterprise: International Trade 2023, which was received for the company’s outstanding growth in international trade.
Natalie Winfield, Executive Vice President, Commercial Operations, at Domainex, commented: “Having worked at Domainex for nearly 20 years, it has been amazing to witness the changes and growth achieved. When I first joined, we were a small company, and now we have two sites, over 100 staff and serve a global client base. We are delighted to be included in this special report. The growth we achieved during the 10 years was driven by the high-quality services we deliver to our clients. I want to thank our customers for trusting us with their critical projects and the whole Domainex team for their continued commitment to innovative research and for their hard work and dedication.”
ENDS
For further information, please contact:
Dr Natalie Winfield
Executive Vice President, Commercial Operations
T: +44 (0) 1223 433180
E: enquiries@domainex.co.uk
Notes to Editors
About Domainex
Based in Cambridge, UK, Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organizations worldwide. The Company has been setting new standards in research since 2001, collaboratively with pharmaceutical and biotechnology companies, patient foundations, and leading academic institutions globally.
Domainex provides innovative and customised biology and chemistry services to advance its partners’ disease research projects, from target expression to pre-clinical development candidate nomination. Domainex leverages its considerable knowledge of drug discovery to provide intellectual input, creativity, and innovation to maximize the chance of successfully identifying drug candidates to treat debilitating diseases. Domainex works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how, and a wealth of experience to bear on their projects.
Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs.
Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.